Glenmark Pharma (Large Cap - Next Multibagger) Share Target 2024, 2025 To 2039
|
Glenmark Pharmaceuticals Limited |
|||
|
Price: ₹1,541.65 | ||
| 52 Week Low: ₹771.00 52 Week High: ₹1,830.95 |
|||
| Market Capital: 42,120.79 Crore (Largecap) | |||
| Healthcare -> Drug Manufacturers - Specialty & Generic | |||
Show Table of Contents
Table of Contents
- 1: Approach 1: Technical Analysis Paired With Price Action
- 1.1: Glenmark Pharma Share Price Target For 2024
- 1.1.1: Glenmark Pharma Share Price Target Table For 2024
- 1.1.2: Short-Term Technical Outlook
- 1.2: Glenmark Pharma Share Price Target For 2025
- 1.2.1: Glenmark Pharma Share Price Target Table For 2025
- 1.2.2: Long-Term Technical Outlook
- 2: Approach 2: Machine Learning By Studying Historical Prices
- 2.1: Glenmark Pharma Share Price Target Chart and Table From 2024, 2025, 2026 to 2039
- 3: Glenmark Pharma Brief Company Overview
- 4: Glenmark Pharma Financial Performance
- 4.0.1: Is Glenmark Pharma A Good Buy For Long Term?
To predict the Glenmark Pharma's future market prices, we harnessed 2 dynamic approaches:
Approach 1: Technical Analysis Paired With Price Action
Approach 2: Machine Learning By Studying Historical Prices
Approach 1: Technical Analysis Paired With Price Action
Glenmark Pharma Share Price Target For 2024
The line chart displays the monthly closing prices of Glenmark Pharma with a black line. The green line shows three potential target prices for 2024, while the red line indicates three potential Stop Loss levels.
For detailed target and stop loss values for Glenmark Pharma shares in 2024, see the table below.
Glenmark Pharma Share Price Target Table For 2024
| Level | Value | Analysis |
|---|---|---|
| 2024 Target 3 | 1617.23 (+4.90%) | Technical Indicator: MA50 |
| 2024 Target 2 | 1597.05 (+3.59%) | Price Action: 18 Nov 2024 High |
| 2024 Target 1 | 1568.8 (+1.76%) | Price Action: 03 Dec 2024 High |
| Current Price | 1541.65 | Glenmark Pharma's share price as of 20 Dec 2024 |
| Stop Loss 1 | 1533.45 (-0.54%) | Price Action: 20 Dec 2024 Low |
| Stop Loss 2 | 1517.69 (-1.56%) | Price Action: 19 Nov 2024 High |
| Stop Loss 3 | 1502.3 (-2.56%) | Price Action: 16 Dec 2024 Low |
Short-Term Technical Outlook
Current Technical Position: Glenmark Pharma is showing mixed momentum signals near key moving averages.
Key Technical Level: The 25-day moving average at ₹1522.3 serves as the nearest technical reference point.
Historical Returns: 3-month: -7.75% | 6-month: +25.47% | 1-year: +80.79%
Glenmark Pharma Share Price Target For 2025
The line chart displays the monthly closing prices of Glenmark Pharma with a black line. The green line shows three potential target prices for 2025, while the red line indicates three potential Stop Loss levels.
For detailed target and stop loss values for Glenmark Pharma shares in 2025, see the table below.
Glenmark Pharma Share Price Target Table For 2025
| Level | Value | Analysis |
|---|---|---|
| 2025 Target 3 | 2300.72 (+49.23%) | Price Action: Chart |
| 2025 Target 2 | 2257.82 (+46.45%) | Price Action: Chart |
| 2025 Target 1 | 2235.47 (+45.00%) | Fibonacci Extension Level 64.90% |
| Current Price | 1541.65 | Glenmark Pharma's share price as of 20 Dec 2024 |
| Stop Loss 1 | 1380.35 (-10.47%) | Technical Indicator: MA200 |
| Stop Loss 2 | 1366.55 (-11.36%) | Price Action: Chart |
| Stop Loss 3 | 1341.95 (-12.96%) | Price Action: Chart |
Long-Term Technical Outlook
52-Week Range Analysis: Glenmark Pharma is currently trading at 72.7% of its 52-week range (₹771 - ₹1830.95).
Long-Term Trend Analysis: The stock is maintaining a bullish long-term trend, trading above both 150-day and 250-day moving averages.
Long-Term Performance: 1-year: +80.79% | 3-year: +194.84% | 5-year: +352.92%
Stay ahead of the market! Get instant alerts on crucial market breakouts. Don't miss out on key opportunities!
Your phone number will be HIDDEN to other users.
Approach 2: Machine Learning By Studying Historical Prices
Glenmark Pharma Share Price Target Chart and Table From 2024, 2025, 2026 to 2039
| Year | Target 1 | Target 1 YoY Chg % | Target 2 |
|---|---|---|---|
| Current Price | ₹1,541.65 | ||
| 2024 | ₹1,743.86 | +13.12% | ₹1,770.02 |
| 2025 | ₹2,665.75 | +52.86% | ₹2,705.74 |
| 2026 | ₹3,548.35 | +33.11% | ₹3,601.58 |
| 2027 | ₹4,132.68 | +16.47% | ₹4,194.67 |
| 2028 | ₹4,931.77 | +19.34% | ₹5,005.75 |
| 2029 | ₹5,656.27 | +14.69% | ₹5,761.98 |
| 2030 | ₹6,794.05 | +20.12% | ₹6,895.96 |
| 2031 | ₹7,743.98 | +13.98% | ₹7,860.14 |
| 2032 | ₹8,084.66 | +4.40% | ₹8,205.93 |
| 2033 | ₹8,890.72 | +9.97% | ₹9,024.08 |
| 2034 | ₹9,568.67 | +7.63% | ₹9,929.70 |
| 2035 | ₹10,922.36 | +14.15% | ₹11,086.20 |
| 2036 | ₹11,939.62 | +9.31% | ₹12,118.71 |
| 2037 | ₹12,036.63 | +0.81% | ₹12,217.18 |
| 2038 | ₹12,849.67 | +6.75% | ₹13,082.12 |
| 2039 | ₹13,792.63 | +7.34% | ₹14,132.93 |
Note: Target 1 and Target 2 represent price levels that the stock is most likely to achieve during the respective year, based on machine learning algorithms analyzing historical price patterns and market behavior. These predictions are generated through comprehensive analysis of the stock's historical data using advanced ML models.
Glenmark Pharma Brief Company Overview
Glenmark Pharmaceuticals: A Global Pharmaceutical Leader Established in 1977, Glenmark Pharmaceuticals has emerged as a prominent player in the global pharmaceutical industry. Headquartered in Mumbai, India, the company possesses a substantial market presence across multiple...
regions, including North America, Latin America, Europe, Japan, and international markets. Glenmark's diversified product range encompasses both branded and generic formulations, specializing in therapeutic areas such as dermatology, respiratory, and oncology. Branded Formulations: Glenmark offers a portfolio of innovative branded products, including Ryaltris nasal spray for seasonal allergic rhinitis. Generic Formulations: The company's generic formulations provide affordable access to essential medicines in various therapeutic categories. Active Pharmaceutical Ingredients: Glenmark manufactures a range of active pharmaceutical ingredients, serving as a key supplier to the global pharmaceutical market. Glenmark's commitment to innovation and research is evident in its robust product pipeline, which includes several promising drug candidates in Phase 1 and 2 clinical trials. The company's reputation for excellence and customer focus has garnered widespread recognition within the pharmaceutical industry, solidifying its position as a reliable and trusted partner in healthcare.Glenmark Pharma Financial Performance
| Metric | Value | Description |
|---|---|---|
| Market Capital | 42,120.79 Crore | Market valuation of Glenmark Pharma's shares. |
| Revenue (TTM) | 12,861.21 Crore | Total revenue generated by Glenmark Pharma over the past twelve months. |
| Net Income (TTM) | -15,732,129,792.00 | Net Profit or Loss after all the expenses over the past twelve months. |
| Operating Margin | +14.50% | Income from operations as a percentage of revenue, before taxes and interest. |
| Profit Margin | -10.20% | Net income as a percentage of revenue, after all expenses. |
| Revenue Growth (Quarterly) |
-4.60% | Change in revenue compared to the previous quarter. |
| Earnings Growth (YOY Quarterly) |
+126.90% | Change in earnings compared to the same quarter last year. |
| Debt-to-Equity (D/E) Ratio |
15.68 | Company's total debt divided by total shareholder equity. |
| Total Debt | 1,230.93 Crore | Sum of Glenmark Pharma's current & long-term financial obligations. |
| Total Cash | 1,659.45 Crore | Total amount of liquid funds available to Glenmark Pharma. |
| Beta | 0.88 | Beta is less than 1 indicating that the Glenmark Pharma's price is less volatile than the market. |
Is Glenmark Pharma A Good Buy For Long Term?
Glenmark Pharma presents a mixed picture for long-term investors. While its market capitalization is substantial (₹42,120.79 crore) and past returns are impressive (97.68% in the last 12 months, 199.53% over three years), a significant net loss of ₹1,573.21 crore in the last 12 months (TTM) and a negative profit margin (-10.2%) raise concerns. Although it holds a cash balance of ₹1,659.45 crore against a debt of ₹1,230.93 crore (Q2 2024-25), the substantial loss needs further investigation before considering it a "good buy". More in-depth analysis of the reasons for the loss is crucial before making a long-term investment decision. Therefore, it's currently an average buy at best.
Disclaimer: The information provided on this page is for educational purposes only and should not be considered as financial advice. Historical performance data and technical analysis cannot guarantee future results. Stock investments are subject to market risks. Please consult with a qualified financial advisor before making any investment decisions.
All stock data shown is sourced from publicly available information and while we strive for accuracy, we cannot guarantee the absolute accuracy of all figures. Users should verify critical information from official sources before making investment decisions.
